Good as gold.

We all know that pharmaceutical companies are rolling in money by overcharging us for all the medicines we depend on or have been told we depend on. Which is why they push so hard. This week I haven't been able to look up anything on YouTube without first having to view a commercial—at least for five seconds—for Invokana, a new cash cow from Janssen. Used along with diet and exercise, INVOKANA® is the first in the newest class of diabetes medicines that’s proven to significantly lower A1C in adults with type 2 diabetes. That makes it highly desirable and much needed, which is exactly what greedy pharmaceuticals require in order to soak the sick. (30 pills, $371.00.) Fortunately I don't
have diabetes so their ads are wasted on me.